Beyond AAV, non-AAV vectors, such as herpes simplex virus (HSV) and adenovirus, are actively explored in cancer trials.
First-pass extracted concept
adenovirus vectors
Candidate: concept label1 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
adenovirus
Evidence Snippets
Supporting Sources
Linked Claims
HSV and adenovirus vectors are actively explored in cancer trials.
Since 2021, the FDA has approved seven new viral vector-based gene therapies.
Viral vector technologies are maturing from proof-of-concept studies toward precision platforms capable of addressing rare monogenic disorders and more prevalent complex diseases.